157 related articles for article (PubMed ID: 37197964)
21. Case 25-2021: A 48-Year-Old Man with Fatigue and Leg Swelling.
Moore AB; Wing JR; Goiffon RJ; Leaf RK; Tsao L; Misdraji J
N Engl J Med; 2021 Aug; 385(8):745-754. PubMed ID: 34407347
[No Abstract] [Full Text] [Related]
22. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association.
Pennell DJ; Udelson JE; Arai AE; Bozkurt B; Cohen AR; Galanello R; Hoffman TM; Kiernan MS; Lerakis S; Piga A; Porter JB; Walker JM; Wood J;
Circulation; 2013 Jul; 128(3):281-308. PubMed ID: 23775258
[TBL] [Abstract][Full Text] [Related]
23. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
Kontoghiorghes GJ; Spyrou A; Kolnagou A
Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
[TBL] [Abstract][Full Text] [Related]
24. [Refractory heart failure in a 26-year-old woman with idiopathic hemochromatosis].
Oliveira e Silva A; Maciel L; Fernandes E; Pina R; Candeias O; de Freitas F
Rev Port Cardiol; 1994 Oct; 13(10):771-5; 736-7. PubMed ID: 7833064
[TBL] [Abstract][Full Text] [Related]
25. Iron overload cardiomyopathy: Using the latest evidence to inform future applications.
Kumfu S; Chattipakorn SC; Chattipakorn N
Exp Biol Med (Maywood); 2022 Apr; 247(7):574-583. PubMed ID: 35130741
[TBL] [Abstract][Full Text] [Related]
26. Heart failure and malignant ventricular tachyarrhythmias due to hereditary hemochromatosis with iron overload cardiomyopathy.
Demant AW; Schmiedel A; Büttner R; Lewalter T; Reichel C
Clin Res Cardiol; 2007 Dec; 96(12):900-3. PubMed ID: 17694379
[No Abstract] [Full Text] [Related]
27. Type 4B hereditary hemochromatosis due to heterozygous p.D157A mutation in SLC40A1 complicated with hypopituitarism.
Honma Y; Karasuyama T; Kumamoto K; Shimajiri S; Toki Y; Tatsumi Y; Sumida K; Koikawa K; Morino K; Oe S; Miyagawa K; Yamasaki M; Shibata M; Abe S; Ikuta K; Hayashi H; Harada M
Med Mol Morphol; 2021 Mar; 54(1):60-67. PubMed ID: 32607777
[TBL] [Abstract][Full Text] [Related]
28. Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease.
Kelly AL; Rhodes DA; Roland JM; Schofield P; Cox TM
QJM; 1998 Sep; 91(9):607-18. PubMed ID: 10024915
[TBL] [Abstract][Full Text] [Related]
29. Comparing Care of the Primary and Secondary Hemochromatosis Patients.
Becker S
J Infus Nurs; 2020; 43(2):65-69. PubMed ID: 32106193
[TBL] [Abstract][Full Text] [Related]
30. Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
Quarta A; Melpignano A; Quarta G
Acta Haematol; 2011; 125(4):219-21. PubMed ID: 21266801
[TBL] [Abstract][Full Text] [Related]
31. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.
Phatak P; Brissot P; Wurster M; Adams PC; Bonkovsky HL; Gross J; Malfertheiner P; McLaren GD; Niederau C; Piperno A; Powell LW; Russo MW; Stoelzel U; Stremmel W; Griffel L; Lynch N; Zhang Y; Pietrangelo A
Hepatology; 2010 Nov; 52(5):1671-779. PubMed ID: 20814896
[TBL] [Abstract][Full Text] [Related]
32. Marked iron in liver explants in the absence of major hereditary hemochromatosis gene defects: a risk factor for cardiac failure.
Fenton H; Torbenson M; Vivekanandan P; Yeh MM; Hart J; Ferrell L
Transplantation; 2009 Apr; 87(8):1256-60. PubMed ID: 19384175
[TBL] [Abstract][Full Text] [Related]
33. Recurrence of iron deposition in the cardiac allograft in a patient with non-HFE hemochromatosis.
Kuppahally SS; Hunt SA; Valantine HA; Berry GJ
J Heart Lung Transplant; 2006 Jan; 25(1):144-7. PubMed ID: 16399547
[TBL] [Abstract][Full Text] [Related]
34. Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
Nijjar PS; Vongooru H; Tamene A; Valeti U; Masri C
Minn Med; 2015 Jul; 98(7):47. PubMed ID: 26267924
[No Abstract] [Full Text] [Related]
35. Hereditary hemochromatosis.
Walker EM; Wolfe MD; Norton ML; Walker SM; Jones MM
Ann Clin Lab Sci; 1998; 28(5):300-12. PubMed ID: 9784832
[TBL] [Abstract][Full Text] [Related]
36. Idiopathic hemochromatosis. II. Diagnosis and treatment.
Can Med Assoc J; 1967 Jun; 96(25):1642-3. PubMed ID: 6027628
[No Abstract] [Full Text] [Related]
37. Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: improvement of liver disease activity, cardiac and hematological function.
Maeda T; Nakamaki T; Saito B; Nakashima H; Ariizumi H; Yanagisawa K; Hattori A; Tatsumi Y; Hayashi H; Suzuki K; Tomoyasu S
Eur J Haematol; 2011 Nov; 87(5):467-9. PubMed ID: 21848699
[No Abstract] [Full Text] [Related]
38. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption [Kontoghiorghes GJ, Spyrou A, Kolganou A. Hemoglobin. 2010;34(3); 251-264].
Nick HP
Hemoglobin; 2011; 35(2):175-9. PubMed ID: 21417578
[No Abstract] [Full Text] [Related]
39. [Hemochromatosis associated with hereditary spherocytosis].
López DE; Kohan M; Ferreño D; Raffa MP; Prytyka A
Acta Gastroenterol Latinoam; 1997; 27(4):267-70. PubMed ID: 9580054
[TBL] [Abstract][Full Text] [Related]
40. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
Nick H; Allegrini PR; Fozard L; Junker U; Rojkjaer L; Salie R; Niederkofler V; O'Reilly T
Exp Biol Med (Maywood); 2009 May; 234(5):492-503. PubMed ID: 19234060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
